Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Ringgit opens higher against US dollar, other major currencies

The local currency edges up to 4.0360/4.0410, supported by Malaysia’s strong economic data.

Ringgit opens higher against US dollar, other major currencies

KUALA LUMPUR: The Malaysian ringgit opened higher against the US dollar and other major currencies on Monday, according to an analyst. The local currency climbed to 4.0360/4.0410 against the US dollar from Friday's closing rate of 4.0365/4.0405. Bank Muamalat Malaysia Bhd chief economist Afzanizam Abdul Rashid stated that the ringgit was anticipated to maintain its strong support in the short term due to robust macroeconomic data.

This includes July's export figures, which could indicate an upward revision in economic growth for the latter half of the year. Afzanizam noted that the ringgit might attempt to surpass the RM4.03 level today. He emphasized that market participants would closely monitor long-term US Treasury yields, as efforts to directly lower market interest rates may face obstacles due to US government debt surpassing $40 trillion.

Additionally, investors would pay significant attention to the Jackson Hole Symposium, scheduled from August 27 to 29, for potential insights into the US Federal Reserve's actions at its September meeting. The ringgit showed a positive trend against a range of currencies, including the Japanese yen, British pound, and euro, while its performance against regional currencies like the Singapore dollar, Indonesian rupiah, Philippine peso, and Thai baht varied.

Written by urgent.news from Free Malaysia Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at freemalaysiatoday.com →

More in Finance & Markets

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs.

  • Symbiotec Pharmalab raising ₹150 crore through IPO for debt repayment
  • Company specializes in APIs, nutritional ingredients, specialty products
  • Global leader in corticosteroid and steroidal-hormone APIs with 38.2% market share

More from Monday 24 August →